Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01493505
Other study ID # 20101129
Secondary ID TRINOVA-3 201011
Status Terminated
Phase Phase 3
First received September 29, 2011
Last updated February 22, 2017
Start date January 2012
Est. completion date December 2016

Study information

Verified date February 2017
Source Amgen
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine whether AMG 386 or AMG 386 Placebo in combination with Paclitaxel and Carboplatin are effective in the treatment of ovarian cancer.


Recruitment information / eligibility

Status Terminated
Enrollment 1015
Est. completion date December 2016
Est. primary completion date March 2016
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Female subjects 18 years of age or older with FIGO Stages III-IV epithelial ovarian, primary peritoneal or fallopian tube cancer with an indication for first-line treatment with paclitaxel and carboplatin x 6 cycles (Subjects with pseudomyxoma, mesothelioma, adenocarcinoma with an unknown primary tumour, carcinosarcoma, sarcoma, mucinous or neuroendocrine histology are excluded

- Subjects with FIGO Stage IIIA or IIIB disease must have undergone PDS for ovarian, primary peritoneal or fallopian tube cancer within 12 weeks prior to randomization

- Subjects with FIGO Stage IIIC or IV disease must either:

- Undergo PDS for epithelial ovarian, primary peritoneal or fallopian tube cancer within 12 weeks prior to randomization or

- Plan to have IDS following 3 cycles of paclitaxel and carboplatin plus AMG 386 or AMG 386 placebo for biopsy proven epithelial ovarian, primary peritoneal or fallopian tube cancer

- ECOG performance status of 0 or 1

- Adequate bone marrow, renal and hepatic function

Exclusion Criteria:

- Prior use of any anticancer therapy or experimental therapy for epithelial ovarian, primary peritoneal or fallopian tube cancer

- Previous abdominal and/or pelvic external beam radiotherapy

- History of central nervous metastasis

- History of arterial or venous thromboembolism within 12 months prior to randomization

- Clinically significant cardiovascular disease within 12 months prior to randomization

Study Design


Intervention

Drug:
AMG 386
AMG 386 15mg/kg IV QW (until progression or unacceptable toxicity develops)
Paclitaxel
Paclitaxel 175 mg/m2 3 hour IV Q3W (6 cycles)
AMG 386 Placebo
AMG 386 Placebo IV QW (until progression or unacceptable toxicity develops)
Carboplatin
Carboplatin AUC 5 or 6 IV Q3W (6 cycles)

Locations

Country Name City State
Austria Research Site Graz
Austria Research Site Graz
Austria Research Site Innsbruck
Austria Research Site Linz
Austria Research Site Linz
Austria Research Site Salzburg
Austria Research Site Wien
Belgium Research Site Bonheiden
Belgium Research Site Brasschaat
Belgium Research Site Bruxelles
Belgium Research Site Charleroi
Belgium Research Site Duffel
Belgium Research Site Edegem
Belgium Research Site Gent
Belgium Research Site Hasselt
Belgium Research Site Kortrijk
Belgium Research Site Leuven
Belgium Research Site Libramont
Belgium Research Site Liège
Belgium Research Site Namur
Belgium Research Site Oostende
Belgium Research Site Sint-Niklaas
Belgium Research Site Turnhout
Belgium Research Site Wilrijk
Belgium Research Site Yvoir
Canada Research Site Calgary Alberta
Canada Research Site Edmonton Alberta
Canada Research Site Halifax Nova Scotia
Canada Research Site Kingston Ontario
Canada Research Site London Ontario
Canada Research Site Montreal Quebec
Canada Research Site Quebec
Canada Research Site Sault Ste. Marie Ontario
Canada Research Site Toronto Ontario
Canada Research Site Toronto Ontario
Denmark Research Site Herlev
Denmark Research Site København Ø
Denmark Research Site Roskilde
Germany Research Site Berlin
Germany Research Site Dresden
Germany Research Site Düsseldorf
Germany Research Site Düsseldorf
Germany Research Site Erlangen
Germany Research Site Essen
Germany Research Site Essen
Germany Research Site Frankfurt am Main
Germany Research Site Frankfurt am Main
Germany Research Site Freiburg
Germany Research Site Hamburg
Germany Research Site Hannover
Germany Research Site Hannover
Germany Research Site Kiel
Germany Research Site Konstanz
Germany Research Site Leipzig
Germany Research Site Ludwigsburg
Germany Research Site München
Germany Research Site München
Germany Research Site München
Germany Research Site Oldenburg
Germany Research Site Ravensburg
Germany Research Site Rostock
Germany Research Site Stuttgart
Germany Research Site Tübingen
Germany Research Site Ulm
Greece Research Site Athens
Greece Research Site Athens
Greece Research Site Athens
Greece Research Site Athens
Greece Research Site Larissa
Greece Research Site Patra
Greece Research Site Thessaloniki
Hong Kong Research Site Hong Kong
Hong Kong Research Site Kowloon
Hong Kong Research Site New Territories
Italy Research Site Avellino
Italy Research Site Aviano PN
Italy Research Site Bari
Italy Research Site Bologna
Italy Research Site Brescia
Italy Research Site Genova
Italy Research Site Milano
Italy Research Site Milano
Italy Research Site Napoli
Italy Research Site Novara
Italy Research Site Palermo
Italy Research Site Pisa
Italy Research Site Roma
Italy Research Site Roma
Italy Research Site Torino
Japan Research Site Fukuoka-shi Fukuoka
Japan Research Site Kashiwa Chiba
Japan Research Site Kitaadachi-gun Saitama
Japan Research Site Kure-city Hiroshima
Japan Research Site Kurume-city Fukuoka
Japan Research Site Morioka-city Iwate
Japan Research Site Nagoya-city Aichi
Japan Research Site Sapporo-city Hokkaido
Japan Research Site Suntou-gun Shizuoka
Japan Research Site Tokyo
Japan Research Site Tokyo
Japan Research Site Yonago-city Tottori
Korea, Republic of Research Site Goyang-si, Gyeonggi-do
Korea, Republic of Research Site Seoul
Korea, Republic of Research Site Seoul
Korea, Republic of Research Site Seoul
Netherlands Research Site Deventer
Netherlands Research Site Leiden
Netherlands Research Site Nijmegen
Netherlands Research Site Rotterdam
Russian Federation Research Site Chelyabinsk
Russian Federation Research Site Ivanovo
Russian Federation Research Site Krasnodar
Russian Federation Research Site Moscow
Russian Federation Research Site Obninsk
Russian Federation Research Site Pyatigorsk
Russian Federation Research Site Saint Petersburg
Russian Federation Research Site Ufa
Russian Federation Research Site Voronezh
Spain Research Site Badalona Cataluña
Spain Research Site Barcelona Cataluña
Spain Research Site El Palmar Murcia
Spain Research Site Girona Cataluña
Spain Research Site Lleida Cataluña
Spain Research Site Madrid
Spain Research Site Madrid
Spain Research Site Madrid
Spain Research Site Madrid
Spain Research Site Madrid
Spain Research Site Madrid
Spain Research Site Madrid
Spain Research Site Madrid
Spain Research Site Oviedo Asturias
Spain Research Site Palma de Mallorca Baleares
Spain Research Site Valencia Comunidad Valenciana
Spain Research Site Valencia Comunidad Valenciana
Spain Research Site Valencia Comunidad Valenciana
Spain Research Site Zaragoza Aragón
United States Research Site Abington Pennsylvania
United States Research Site Akron Ohio
United States Research Site Albany New York
United States Research Site Albuquerque New Mexico
United States Research Site Albuquerque New Mexico
United States Research Site Ames Iowa
United States Research Site Anchorage Alaska
United States Research Site Annandale Virginia
United States Research Site Asheville North Carolina
United States Research Site Augusta Georgia
United States Research Site Aurora Colorado
United States Research Site Austin Texas
United States Research Site Austin Texas
United States Research Site Baltimore Maryland
United States Research Site Baltimore Maryland
United States Research Site Baltimore Maryland
United States Research Site Bedford Texas
United States Research Site Bend Oregon
United States Research Site Berkeley California
United States Research Site Bethlehem Pennsylvania
United States Research Site Billings Montana
United States Research Site Birmingham Alabama
United States Research Site Boston Massachusetts
United States Research Site Bridgeport Connecticut
United States Research Site Brightwaters New York
United States Research Site Bronx New York
United States Research Site Buffalo New York
United States Research Site Burbank California
United States Research Site Burlington Massachusetts
United States Research Site Burlington North Carolina
United States Research Site Burlington Vermont
United States Research Site Canton Ohio
United States Research Site Chapel Hill North Carolina
United States Research Site Charleston South Carolina
United States Research Site Charlotte North Carolina
United States Research Site Charlottesville Virginia
United States Research Site Chattanooga Tennessee
United States Research Site Chicago Illinois
United States Research Site Chicago Illinois
United States Research Site Chicago Illinois
United States Research Site Cincinnati Ohio
United States Research Site Cincinnati Ohio
United States Research Site Clearwater Florida
United States Research Site Cleveland Ohio
United States Research Site Cleveland Ohio
United States Research Site Cleveland Ohio
United States Research Site Columbia South Carolina
United States Research Site Columbus Ohio
United States Research Site Columbus Ohio
United States Research Site Concord North Carolina
United States Research Site Concord California
United States Research Site Corona California
United States Research Site Covington Louisiana
United States Research Site Dallas Texas
United States Research Site Dallas Texas
United States Research Site Dallas Texas
United States Research Site Danvers Massachusetts
United States Research Site Decatur Illinois
United States Research Site Detroit Michigan
United States Research Site Detroit Michigan
United States Research Site Durham North Carolina
United States Research Site Edgewood Kentucky
United States Research Site Englewood Colorado
United States Research Site Evanston Illinois
United States Research Site Fargo North Dakota
United States Research Site Farmington Connecticut
United States Research Site Gainesville Georgia
United States Research Site Galveston Texas
United States Research Site Gilbert Arizona
United States Research Site Green Bay Wisconsin
United States Research Site Green Bay Wisconsin
United States Research Site Greenville South Carolina
United States Research Site Greenville South Carolina
United States Research Site Hackensack New Jersey
United States Research Site Hartford Connecticut
United States Research Site Hinsdale Illinois
United States Research Site Hollywood Florida
United States Research Site Honolulu Hawaii
United States Research Site Houston Texas
United States Research Site Indianapolis Indiana
United States Research Site Indianapolis Indiana
United States Research Site Indianapolis Indiana
United States Research Site Iowa City Iowa
United States Research Site Jackson Mississippi
United States Research Site Jamaica New York
United States Research Site Joliet Illinois
United States Research Site Kalamazoo Michigan
United States Research Site Kansas City Missouri
United States Research Site Kansas City Kansas
United States Research Site Kettering Ohio
United States Research Site La Jolla California
United States Research Site Lafayette Louisiana
United States Research Site Lake Success New York
United States Research Site Las Vegas Nevada
United States Research Site Lebanon New Hampshire
United States Research Site Lexington Kentucky
United States Research Site Lincoln Nebraska
United States Research Site Long Beach California
United States Research Site Los Angeles California
United States Research Site Macon Georgia
United States Research Site Marshfield Wisconsin
United States Research Site Mayfield Heights Ohio
United States Research Site Maywood Illinois
United States Research Site Miami Florida
United States Research Site Milwaukee Wisconsin
United States Research Site Milwaukee Wisconsin
United States Research Site Milwaukee Wisconsin
United States Research Site Minneapolis Minnesota
United States Research Site Mobile Alabama
United States Research Site Munster Indiana
United States Research Site Neptune New Jersey
United States Research Site New Britain Connecticut
United States Research Site New York New York
United States Research Site New York New York
United States Research Site New York New York
United States Research Site Norfolk Virginia
United States Research Site Oak Lawn Illinois
United States Research Site Ogden Utah
United States Research Site Oklahoma City Oklahoma
United States Research Site Orange California
United States Research Site Orlando Florida
United States Research Site Orlando Florida
United States Research Site Oshkosh Wisconsin
United States Research Site Oxnard California
United States Research Site Park Ridge Illinois
United States Research Site Peoria Arizona
United States Research Site Philadelphia Pennsylvania
United States Research Site Philadelphia Pennsylvania
United States Research Site Phoenix Arizona
United States Research Site Phoenix Arizona
United States Research Site Pittsburgh Pennsylvania
United States Research Site Pittsburgh Pennsylvania
United States Research Site Providence Rhode Island
United States Research Site Radnor Pennsylvania
United States Research Site Rancho Mirage California
United States Research Site Reno Nevada
United States Research Site Roanoke Virginia
United States Research Site Rochester Minnesota
United States Research Site Sacramento California
United States Research Site Sacramento California
United States Research Site San Antonio Texas
United States Research Site San Diego California
United States Research Site Savannah Georgia
United States Research Site Scarborough Maine
United States Research Site Seattle Washington
United States Research Site Sheboygan Wisconsin
United States Research Site Sioux Falls South Dakota
United States Research Site South Bend Indiana
United States Research Site St Louis Missouri
United States Research Site St Petersburg Florida
United States Research Site St. Louis Park Minnesota
United States Research Site Stamford Connecticut
United States Research Site Syracuse New York
United States Research Site Tacoma Washington
United States Research Site Tampa Florida
United States Research Site The Woodlands Texas
United States Research Site Toledo Ohio
United States Research Site Tucson Arizona
United States Research Site Tucson Arizona
United States Research Site Tulsa Oklahoma
United States Research Site Urbana Illinois
United States Research Site Voorhees New Jersey
United States Research Site Waukesha Wisconsin
United States Research Site Wausau Wisconsin
United States Research Site Wenatchee Washington
United States Research Site West Allis Wisconsin
United States Research Site West Reading Pennsylvania
United States Research Site Wilmington North Carolina
United States Research Site Winchester Virginia
United States Research Site Winston Salem North Carolina
United States Research Site Winston Salem North Carolina
United States Research Site Woodbridge Virginia
United States Research Site Worcester Massachusetts

Sponsors (1)

Lead Sponsor Collaborator
Amgen

Countries where clinical trial is conducted

United States,  Austria,  Belgium,  Canada,  Denmark,  Germany,  Greece,  Hong Kong,  Italy,  Japan,  Korea, Republic of,  Netherlands,  Russian Federation,  Spain, 

References & Publications (1)

Fujiwara K, Monk BJ, Lhommé C, Coleman RL, Brize A, Oaknin A, Ray-Coquard I, Fabbro M, Provencher D, Bamias A, Vergote I, DeCensi A, Zhang K, Vogl FD, Bach BA, Raspagliesi F. Health-related quality of life in women with recurrent ovarian cancer receiving paclitaxel plus trebananib or placebo (TRINOVA-1). Ann Oncol. 2016 Jun;27(6):1006-13. doi: 10.1093/annonc/mdw147. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Progression free survival 3 years
Secondary Overall survival (OS) 5 years
Secondary Incidence of adverse events and significant laboratory abnormalities 4 years
Secondary Pharmacokinetics of AMG 386 (Cmax and Cmin) pre-dose weeks 1, 7, 10, 19 and within 10 minutes post dose week 1, 7 1 year
Secondary Incidence of anti-AMG 386 antibody formation pre-dose weeks 1, 10, 19 4 years
Secondary Patient reported ovarian cancer-specific symptoms and health related quality of life 4 years
Secondary Patient reported status as measured by the EuroQOL (EQ-5D) 4 years
Secondary AMG 386 exposure-response relationships for PFS and OS 4 years
Secondary Correlation of serum biomarkers with measures of response 4 years
See also
  Status Clinical Trial Phase
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Withdrawn NCT05201001 - APX005M in Patients With Recurrent Ovarian Cancer Phase 2
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Not yet recruiting NCT06376253 - A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers Phase 1
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT05156892 - Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer Phase 1
Suspended NCT02432378 - Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines Phase 1/Phase 2
Recruiting NCT04533763 - Living WELL: A Web-Based Program for Ovarian Cancer Survivors N/A
Active, not recruiting NCT03371693 - Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer Phase 3
Withdrawn NCT03032614 - Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients Phase 2
Completed NCT02019524 - Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients Phase 1
Completed NCT01936363 - Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer Phase 2
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT05059522 - Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing Phase 3
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Terminated NCT04586335 - Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Phase 1
Terminated NCT03146663 - NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer Phase 2